The curious case of Aspen pharmaceuticals and excessive pricing

Click here to read the full article online

In the current piece, the author will first briefly explain some relevant jurisprudence regarding excessive pricing, before analysing more closely the Aspen case and its outcome. The current case is an interesting read, not just because, rather than simply being fined, Aspen offered commitments to reduce the prices of six critical cancer medicines, which were accepted by the Commission, but also because at a moment when the world is in the grip of a deadly virus and life-saving medicines and vaccines are our only way out it has become a necessity to regulate the prices offered by the pharmaceutical industry.